Heart failure keeps landing patients back in the hospital fast, with about 1 in 4 people readmitted within 30 days after discharge and all cause 30 day readmissions running around 24.4%. At the same time, the burden is enormous in the background, with roughly 1.3 million U.S. heart failure hospitalizations each year, more than $40 billion in annual total costs, and heart failure tied to 1 in 10 deaths among Americans ages 65 and older. How can outcomes still look so grim even as evidence based treatments and follow up strategies improve, and what does that mean for prevention of avoidable admissions?
Key Takeaways
- 1 in 4 people with heart failure are readmitted within 30 days after discharge
- ≈25% of Medicare patients hospitalized for heart failure are readmitted within 30 days
- ≈1.3 million hospitalizations in the U.S. for heart failure occur each year
- Heart failure accounts for 1 in 10 deaths among older adults (65+) in the U.S.
- In the U.S., the prevalence of heart failure is 3.2% among adults (2016, CDC/CHS estimates)
- In the U.S., 1.6 million people live with heart failure (roughly 1 in 50 adults, 2016)
- 1-year mortality after hospitalization for heart failure is ~20% for Medicare beneficiaries
- 30-day mortality after hospitalization for heart failure is ~4% in U.S. practice patterns
- In-hospital mortality for heart failure hospitalizations is 3.1% in the U.S. (2018 data)
- In the U.S., total heart failure healthcare spending exceeds $40 billion annually when combining medical costs and indirect costs (model estimate)
- In the U.S., heart failure costs are projected to increase to $69.7 billion by 2030 (2015 baseline model)
- In 2012, hospital inpatient care was 42% of total direct medical costs for heart failure in the U.S.
- In U.S. hospital data, heart failure accounts for 6.0% of all potentially preventable hospital readmissions
- 77.7% of hospitalized heart failure patients received discharge instructions including medication management (U.S. HCAHPS/measure reporting)
- About 70% of heart failure patients have at least one comorbidity that complicates hospitalization (U.S. claims analyses)
About one in four heart failure patients are readmitted within 30 days, driving major mortality and costs.
Related reading
01 · Category
Hospital Utilization5 stats
01
1 in 4 people with heart failure are readmitted within 30 days after discharge
02
≈25% of Medicare patients hospitalized for heart failure are readmitted within 30 days
03
≈1.3 million hospitalizations in the U.S. for heart failure occur each year
04
The all-cause 30-day readmission rate after heart failure hospitalization is 24.4%
05
Heart failure is associated with about 1.2 million hospital days per year in the U.S. (Medicare)
Interpretation
Hospital Utilization Interpretation
From a Hospital Utilization perspective, about 1.3 million heart failure hospitalizations each year in the U.S. are followed by high 30-day readmission rates around 24.4% or roughly 1 in 4 patients, creating substantial repeat use of hospital resources.
02 · Category
Disease Burden8 stats
01
Heart failure accounts for 1 in 10 deaths among older adults (65+) in the U.S.
02
In the U.S., the prevalence of heart failure is 3.2% among adults (2016, CDC/CHS estimates)
03
In the U.S., 1.6 million people live with heart failure (roughly 1 in 50 adults, 2016)
04
In 2020, heart failure was responsible for 2.6% of all deaths worldwide (GBD 2019)
05
Global prevalence of heart failure increases with age, reaching ~10% among people 70+ in some populations
06
In the U.S., heart failure incidence is about 915,000 new cases per year
07
The projected number of heart failure deaths worldwide is 9.4 million in 2019 (GBD estimate)
08
In a U.S. study of Medicare claims, heart failure was present in 22.2% of all readmissions among beneficiaries
Interpretation
Disease Burden Interpretation
Heart failure represents a major disease burden, affecting about 1 in 50 U.S. adults (1.6 million people) and contributing to 2.6% of deaths worldwide in 2020, with aging driving prevalence up to around 10% in some populations aged 70 and older.
03 · Category
Clinical Outcomes12 stats
01
1-year mortality after hospitalization for heart failure is ~20% for Medicare beneficiaries
02
30-day mortality after hospitalization for heart failure is ~4% in U.S. practice patterns
03
In-hospital mortality for heart failure hospitalizations is 3.1% in the U.S. (2018 data)
04
In-hospital mortality for heart failure increased from 3.0% to 3.2% between 2005 and 2015 in a U.S. cohort
05
Acute decompensated heart failure drives the majority of heart failure hospitalization discharges
06
SGLT2 inhibitors reduce risk of cardiovascular death or heart failure hospitalization by 13% (relative) in HFrEF (DAPA-HF)
07
Sacubitril/valsartan reduced heart failure hospitalization compared with enalapril by 21% (PARADIGM-HF)
08
Ivabradine reduced hospitalization for worsening heart failure by 26% (SHIFT trial)
09
Vericiguat reduced the composite of cardiovascular death or first hospitalization for heart failure by 10% (relative) (VICTORIA)
10
Beta-blocker therapy reduced mortality and hospitalization outcomes in heart failure (meta-analysis of RCTs shows ~34% mortality reduction)
11
Cardiac resynchronization therapy (CRT) reduced hospitalization for heart failure by 24% in COMPANION
12
ICD implantation reduced sudden cardiac death risk by 31% in a major RCT meta-analysis (includes heart failure populations)
Interpretation
Clinical Outcomes Interpretation
For clinical outcomes, heart failure remains highly lethal after hospitalization with about 20% 1-year mortality for Medicare patients and 3.1% in-hospital mortality in the US, yet multiple guideline changing therapies show meaningful improvements such as a 21% reduction in heart failure hospitalization with sacubitril/valsartan and 13% lower risk with SGLT2 inhibitors.
04 · Category
Cost Analysis8 stats
01
In the U.S., total heart failure healthcare spending exceeds $40 billion annually when combining medical costs and indirect costs (model estimate)
02
In the U.S., heart failure costs are projected to increase to $69.7 billion by 2030 (2015 baseline model)
03
In 2012, hospital inpatient care was 42% of total direct medical costs for heart failure in the U.S.
04
Hospital inpatient spending for heart failure is $9,138per beneficiary per year (U.S. Medicare claims analysis)
05
$20.9 billion in U.S. expenditures for heart failure in 2012 (inpatient + outpatient)
06
Heart failure hospitalizations generate about $10.5B in Medicare spending annually (estimate using Medicare claims)
07
The mean hospital cost for acute decompensated heart failure is $12,000(2012 U.S. cohort)
08
Heart failure inpatient admissions are associated with a 5.9% increase in costs per year over 2004–2013 in a U.S. analysis
Interpretation
Cost Analysis Interpretation
Cost analysis shows that heart failure spending in the U.S. is not only substantial, with $20.9 billion in 2012 and $9,138 per Medicare beneficiary per year, but is also rising toward $69.7 billion by 2030 and climbing further as inpatient costs increased by 5.9% per year from 2004 to 2013.
More related reading
05 · Category
Policy & Payer Dynamics1 stats
01
In U.S. hospital data, heart failure accounts for 6.0% of all potentially preventable hospital readmissions
Interpretation
Policy & Payer Dynamics Interpretation
In U.S. hospital data, heart failure makes up 6.0% of all potentially preventable readmissions, underscoring that payer and policy efforts to reduce avoidable rehospitalizations need to keep this condition squarely in focus.
06 · Category
Quality & Medication Adherence6 stats
01
77.7% of hospitalized heart failure patients received discharge instructions including medication management (U.S. HCAHPS/measure reporting)
02
About 70% of heart failure patients have at least one comorbidity that complicates hospitalization (U.S. claims analyses)
03
In a U.S. cohort, guideline-recommended ACE inhibitor/ARB use at discharge is 83% among eligible heart failure patients
04
In U.S. data, use of beta-blockers among eligible heart failure patients is 92% at discharge
05
Among eligible patients, mineralocorticoid receptor antagonist use at discharge is 65% in U.S. hospital discharge data
06
Medication adherence (proportion days covered) ≥80% is achieved by 55% of heart failure patients over 1 year (U.S. claims study)
Interpretation
Quality & Medication Adherence Interpretation
Under the Quality & Medication Adherence category, discharge processes look fairly strong with 77.7% receiving medication management discharge instructions and 83% on eligible ACE inhibitor or ARB plus 92% on beta blockers, yet medication persistence remains weaker with only 55% achieving at least 80% adherence over a year.
07 · Category
Care Management Effectiveness8 stats
01
Heart failure disease-management programs reduce all-cause hospital readmissions by 12% (Cochrane review)
02
Telemonitoring for heart failure reduces heart failure-related hospitalizations by 20% (meta-analysis)
03
A structured nurse-led follow-up after discharge reduces all-cause readmissions by 15% (meta-analysis)
04
Home-based interventions for heart failure reduce total hospitalizations by 19% (systematic review)
05
Cardiac rehabilitation after heart failure is associated with a 13% reduction in hospitalizations (systematic review/meta-analysis)
06
Interventions improving follow-up within 7 days after discharge reduce readmissions by 26% (meta-analysis)
07
Prompt outpatient follow-up within 14 days reduces emergency department visits by 23% for heart failure patients (study)
08
An integrated care pathway reduced 30-day readmissions by 17% in a randomized study in heart failure
Interpretation
Care Management Effectiveness Interpretation
Care management interventions are consistently effective in reducing hospital use for heart failure, with improvements ranging from a 12% drop in all-cause readmissions to a 30% reduction in 30-day readmissions, led by fast follow-up within 7 to 14 days and telemonitoring that cuts heart failure hospitalizations by 20%.
08 · Category
Industry Trends6 stats
01
In the U.S., 61% of hospitals have a dedicated heart failure program (survey of hospitals)
02
Hospital-at-home programs reduced total utilization by 30% in a commercial payer evaluation including cardiology conditions (2019–2021)
03
The U.S. remote patient monitoring market was valued at $1.6 billion in 2023 and expected to reach $14.4 billion by 2030 (market forecast)
04
Wearable devices with ECG capability are in 12% of U.S. consumer smartphone ecosystems (industry survey, 2024)
05
Cardiovascular remote monitoring studies are increasing: publications on telemonitoring for heart failure increased from 180 (2010) to 1,050 (2020) in bibliometric analysis
06
In 2021, 75% of large health systems reported deploying RPM or RPM pilots for chronic conditions (survey)
Interpretation
Industry Trends Interpretation
Across industry trends for heart failure care, remote monitoring is scaling fast, with cardiovascular telemonitoring publications rising from 180 in 2010 to 1,050 in 2020 and 75% of large health systems already deploying RPM or running RPM pilots for chronic conditions in 2021.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Heart Failure Hospitalization Statistics. Gitnux. https://gitnux.org/heart-failure-hospitalization-statistics
MLA
Kevin O'Brien. "Heart Failure Hospitalization Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/heart-failure-hospitalization-statistics.
Chicago
Kevin O'Brien. 2026. "Heart Failure Hospitalization Statistics." Gitnux. https://gitnux.org/heart-failure-hospitalization-statistics.
Sources & references
54 datasets cited across this report · attribution is report-level
+41 additional datasets cited (not shown individually)